Table 2 Extent of drug exposure during study
Exposure | Ambrisentan (N = 134) | |||
|---|---|---|---|---|
Primary Evaluation Period | Dosage-adjustment Period | |||
Combined Ambrisentana | Ambrisentan 10 mg | |||
Exposure (days) | n | 134 | 127 | 73 |
Mean (SD) | 83.0 (9.13) | 82.8 (5.59) | 75.8 (16.02) | |
Median | 85.0 | 83.0 | 83.0 | |
Min, Max | 31, 90 | 34, 94 | 27, 87 | |
Range of exposure, n (%) | n | 134 | 127 | 73 |
<=28 days | 0 | 0 | 2 (2.7) | |
29–56 days | 5 (3.7) | 2 (1.6) | 12 (16.4) | |
57–84 days | 37 (27.6) | 90 (70.9) | 44 (60.3) | |
> = 85 days | 92 (68.7) | 35 (27.6) | 15 (20.5) | |
Average of daily dose (mg) | n | 134 | 127 | 73 |
Mean (SD) | 4.95 (0.170) | 7.81 (2.462) | 10.11 (0.346) | |
Median | 4.94 | 9.04 | 10.12 | |
Min, Max | 4.4, 6.5 | 4.8, 11.5 | 8.5, 11.5 | |